Shilpa Medicare zooms on getting GMP Certificate from UK MHRA for Bengaluru facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Shilpa Medicare is currently trading at Rs. 418.35, up by 20.25 points or 5.09% from its previous closing of Rs. 398.10 on the BSE.
The scrip opened at Rs. 406.00 and has touched a high and low of Rs. 424.40 and Rs. 405.40 respectively. So far 41884 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 670.95 on 22-Jul-2021 and a 52 week low of Rs. 380.35 on 07-Mar-2022.
Last one week high and low of the scrip stood at Rs. 424.40 and Rs. 392.75 respectively. The current market cap of the company is Rs. 3622.68 crore.
The promoters holding in the company stood at 50.01%, while Institutions and Non-Institutions held 16.34% and 33.65% respectively.
Shilpa Medicare’s newly commissioned facility for manufacture and testing of Orodispersible films and Transdermal systems situated at Dabaspet, Bengaluru, Karnataka State, has been issued GMP Certificate by UK Medicines and Healthcare products Regulatory Agency (MHRA). The facility was inspected by MHRA from April 18, 2022 to April 20, 2022.
The facility is involved in manufacturing and testing of specialized dosage forms eg. Orodispersible Films and Transdermal systems. The facility is backed up with strong Research and Development of Orodispersible films and transdermal technologies. The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
